Cytochrome P450, family 3, subfamily A, also known as CYP3A, is a human gene locus.[2][3] A homologous locus is found in mice.[4]
The CYP3A locus includes all the known members of the 3A subfamily of the cytochrome P450 superfamily of genes. These genes encode monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The CYP3A cluster consists of four genes:
as well as several extra exons which may or may not be included in transcripts produced from this region. Previously another CYP3A member, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4.[2]
References
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Smith G, Stubbins MJ, Harries LW, Wolf CR (December 1998). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 28 (12): 1129–65.
Lamba JK, Lin YS, Schuetz EG, Thummel KE (November 2002). "Genetic contribution to variable human CYP3A-mediated metabolism". Advanced Drug Delivery Reviews. 54 (10): 1271–94.
Miyazawa M, Shindo M, Shimada T (October 2001). "Roles of cytochrome P450 3A enzymes in the 2-hydroxylation of 1,4-cineole, a monoterpene cyclic ether, by rat and human liver microsomes". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 31 (10): 713–23.
Reid JM, Kuffel MJ, Ruben SL, Morales JJ, Rinehart KL, Squillace DP, Ames MM (September 2002). "Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans". Clinical Cancer Research. 8 (9): 2952–62.
Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD (March 2004). "Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes". Drug Metabolism and Disposition. 32 (3): 359–63.
Somogyi AA, Menelaou A, Fullston SV (October 2004). "CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 34 (10): 875–87.
Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di Rienzo A (2006). "Sequence diversity and haplotype structure at the human CYP3A cluster". The Pharmacogenomics Journal. 6 (2): 105–14.
Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L, Shamlaye C, Burnier M (May 2006). "Association of CYP3A5 genotypes with blood pressure and renal function in African families". Journal of Hypertension. 24 (5): 923–9.
Cheung CY, Op den Buijsch RA, Wong KM, Chan HW, Chau KF, Li CS, Leung KT, Kwan TH, de Vrie JE, Wijnen PA, van Dieijen-Visser MP, Bekers O (June 2006). "Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients". Pharmacogenomics. 7 (4): 563–74.
Watanabe A, Nakamura K, Okudaira N, Okazaki O, Sudo K (July 2007). "Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process". Drug Metabolism and Disposition. 35 (7): 1232–8.
Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D (October 2007). "Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam". Clinical Pharmacology and Therapeutics. 82 (4): 410–26.
